AngioDynamics Reports 2015 Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
AngioDynamics (ANGO) PT, Estimates Cut at Piper Jaffray Following 'Tough' Qtr
April 10, 2015 7:16 AM EDTPiper Jaffray analyst Thomas Gunderson cut estimates and his price target on Neutral-rated AngioDynamics (NASDAQ: ANGO) to $18 (from $21) following a "tough" quarter.
Gunderson commented, "ANGO reported Q3 (Feb) results that were below ours and consensus expectations; Q4 guidance was also lower than Street... More
AngioDynamics (ANGO), EmboMedics Enter Global Microspheres Licensing Agreement
April 9, 2015 4:10 PM EDTAngioDynamics (NASDAQ: ANGO) announced a worldwide licensing agreement with privately-held EmboMedics Inc., of Minneapolis, Minn., which develops injectable and resorbable microspheres. Embolization is the fastest growing segment in Interventional Radiology, and this newly formed strategic relationship will allow AngioDynamics to leverage the talent and knowledge of its sales team to re-enter the approximately $150 million addressable global embolic market.
"AngioDynamics previously helped to build the embolics market, and with worldwide rights to a margin accretive, truly novel technology, we are poised to emulate that success," said Joseph... More
